Published by Global Markets Direct
on Nov 15, 2010
, 50 pages
PDF format - Delivered by Email within 1 business day
Global Markets Direct's, "Type 1 Diabetes Pipeline Review 2010, Q4 2010", provides an overview into the Type 1 Diabetes therapeutic pipeline. This report provides information on the current developmental pipeline, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews the key players and their products under development for Type 1 Diabetes. "Type 1 Diabetes-Pipeline Review 2010, Q4 2010" is built using data and information sourced from Global Markets Direct's proprietary databases, primary and secondary research using Company/University's website, SEC filings, investor presentations and featured press releases, both from company/university sites and industry-specific third party sources, put together with in-house assessment, by Global Markets Direct's team of industry experts.
- A snapshot of the global therapeutic scenario for Type 1 Diabetes.
- Review of the Type 1 Diabetes pipeline products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Includes pipeline products based on various stages of development ranging from discovery till registration stages.
- Includes pipeline projects on the basis of monotherapy and combined therapeutics.
- Study of the Type 1 Diabetes pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand various therapeutics under development for Type 1 Diabetes.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Get an insight into important and diverse types of therapeutics in pipeline for Type 1 Diabetes and understand the trends and players likely to impact the global Type 1 Diabetes market in future.
- Devise corrective measures for pipeline projects by understanding Type 1 Diabetes pipeline depth and focus and the future of Type 1 Diabetes therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
- Avoid Intellectual Property Rights related issues.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.